First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis

J. van Breeschoten, M.W.J.M. Wouters, D.L. Hilarius, J.B. Haanen, C.U. Blank, M.J.B. Aarts, F.W.P.J. van den Berkmortel, J.W.B. de Groot, G.A.P. Hospers, E. Kapiteijn, D. Piersma, R.S. van Rijn, K.P.M. Suijkerbuijk, W.A.M. Blokx, B.J.J. ten Tije, A.A.M. van der Veldt, A. Vreugdenhil, M.J. Boers-Sonderen, A.J.M. van den Eertwegh*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Search results